278 related articles for article (PubMed ID: 21544895)
1. Novel molecular targeted therapies for refractory thyroid cancer.
Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors and the thyroid.
Sherman SI
Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):713-22. PubMed ID: 19942148
[TBL] [Abstract][Full Text] [Related]
3. Early clinical studies of novel therapies for thyroid cancers.
Sherman SI
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):511-24, xi. PubMed ID: 18502340
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Covell LL; Ganti AK
Target Oncol; 2015 Sep; 10(3):311-24. PubMed ID: 26335853
[TBL] [Abstract][Full Text] [Related]
5. Targeted molecular therapies in thyroid carcinoma.
Romagnoli S; Moretti S; Voce P; Puxeddu E
Arq Bras Endocrinol Metabol; 2009 Dec; 53(9):1061-73. PubMed ID: 20126863
[TBL] [Abstract][Full Text] [Related]
6. Rationale and clinical results of multi-target treatments in oncology.
Sartore-Bianchi A; Ricotta R; Cerea G; Maugeri MR; Siena S
Int J Biol Markers; 2007; 22(1 Suppl 4):S77-87. PubMed ID: 17520585
[TBL] [Abstract][Full Text] [Related]
7. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
8. [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Török S; Cserepes T M; Rényi-Vámos F; Döme B
Magy Onkol; 2012 Sep; 56(3):199-208. PubMed ID: 23008829
[TBL] [Abstract][Full Text] [Related]
9. Current and future management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2006 Aug; 4(8):582-3. PubMed ID: 17099615
[No Abstract] [Full Text] [Related]
10. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
12. [KIT and KIT: from biology to clinical use].
Curtit E; Mansi L; Viel E; Dobi E; Chaigneau L; Nguyen T; Pivot X; Blay JY; Kalbacher E
Bull Cancer; 2012 Feb; 99(2):191-7. PubMed ID: 21669561
[TBL] [Abstract][Full Text] [Related]
13. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
[TBL] [Abstract][Full Text] [Related]
15. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
16. [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Török S; Döme B
Magy Onkol; 2012 Mar; 56(1):3-15. PubMed ID: 22403757
[TBL] [Abstract][Full Text] [Related]
17. Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Takami HE
Endocr J; 2011; 58(3):151-3. PubMed ID: 21383525
[TBL] [Abstract][Full Text] [Related]
18. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
19. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Lin CI; Whang EE; Lorch JH; Ruan DT
Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
[TBL] [Abstract][Full Text] [Related]
20. [Oral drugs inhibiting the VEGF pathway].
Ropert S; Mir O; Armand JP
Bull Cancer; 2007 Jul; 94 Spec No():S180-90. PubMed ID: 17846003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]